Market Currents
Sanofi (SNY) and J&J (JNJ) present data for Type 2 diabetes treatments that show they're...
-
Sunday, June 10, 2012, 3:21 AM ETSanofi (SNY) and J&J (JNJ) present data for Type 2 diabetes treatments that show they're more effective in lowering blood-sugar levels than Merck's (MRK) $3.3B market leader Januvia. However, Lantus from Sanofi, which is already approved, and canagliflozin from J&J, which isn't, have their drawbacks.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
